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Abstract
Background: Single nucleotide polymorphisms (SNPs) involved in the estrogen pathway and SNPs in the estrogen
receptor alpha gene (ESR1 6q25) have been linked to breast cancer development, and mammographic density is an
established breast cancer risk factor. Whether there is an association between daily estradiol levels, SNPs in ESR1
and premenopausal mammographic density phenotypes is unknown.
Methods: We assessed estradiol in daily saliva samples throughout an entire menstrual cycle in 202 healthy
premenopausal women in the Norwegian Energy Balance and Breast Cancer Aspects I study. DNA was genotyped
using the Illumina Golden Gate platform. Mammograms were taken between days 7 and 12 of the menstrual cycle,
and digitized mammographic density was assessed using a computer-assisted method (Madena). Multivariable
regression models were used to study the association between SNPs in ESR1, premenopausal mammographic
density phenotypes and daily cycling estradiol.
Results: We observed inverse linear associations between the minor alleles of eight measured SNPs (rs3020364,
rs2474148, rs12154178, rs2347867, rs6927072, rs2982712, rs3020407, rs9322335) and percent mammographic density
(p-values: 0.002–0.026), these associations were strongest in lean women (BMI, ≤23.6 kg/m2.). The odds of above-
median percent mammographic density (>28.5 %) among women with major homozygous genotypes were 3–6 times
higher than those of women with minor homozygous genotypes in seven SNPs. Women with rs3020364major
homozygous genotype had an OR of 6.46 for above-median percent mammographic density (OR: 6.46; 95 % Confidence
Interval 1.61, 25.94) when compared to women with the minor homozygous genotype. These associations were not
observed in relation to absolute mammographic density. No associations between SNPs and daily cycling estradiol were
observed. However, we suggest, based on results of borderline significance (p values: 0.025–0.079) that the level of
17β-estradiol for women with the minor genotype for rs3020364, rs24744148 and rs2982712 were lower throughout
the cycle in women with low (<28.5 %) percent mammographic density and higher in women with high (>28.5 %)
percent mammographic density, when compared to women with the major genotype.
Conclusion: Our results support an association between eight selected SNPs in the ESR1 gene and percent
mammographic density. The results need to be confirmed in larger studies.
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Background
Genetic factors are believed to account for 30–60 % of
the variance in mammographic density [1, 2] while
established breast cancer risk factors such as age, body
mass index (BMI), parity, age at first birth, the use of
hormone therapy and physical activity account for the
remainder of its variability [3]. Substantial evidence sup-
ports the role of ovarian steroid hormones in breast can-
cer [4], and estrogens are associated with breast cancer
development in both pre- and postmenopausal women
[5–7]. Estrogens increase cellular proliferation in breast
tissue, which may increase mammographic density [8].
Mammographic density reflects the proportion of fibro-
glandular cells in the breast tissue; higher density indi-
cates increased potential for proliferative activity [9] and
is an established risk factor for breast cancer [10, 11].
Recently, studies of associations between breast cancer
risk factors and mammographic density has focused not
only on percent mammographic density [12, 13], but on
various mammographic density phenotypes [14–17] as
absolute mammographic density is believed to represent
the actual target tissue for tumor development [18–21].
The genetic determinants of mammographic density
have yet to be identified. A recent combined meta analysis
of data from five genome wide studies (GWAS) among
women of European decent suggests that multiple loci
might be involved [22, 23]. Given the associations between
estrogens and breast cancer, it is plausible that genetic
variation in estrogen receptors may be important.
Both estrogen receptors, alpha (ERα) and beta (ERβ),
are members of the nuclear receptor family of ligand-
inducible transcription factors, but they are believed to
have different transcriptional activation properties [8]. It
has been assumed for a long time that the action of es-
trogens in carcinogenesis is via the ERα signaling and
the proliferation induced by the interaction between es-
trogens and estrogen receptors. [4, 24] Thus, the estro-
gen receptor alpha gene (ESR1), which encodes ERα, is
of special interest in relation to breast cancer initiation,
development, and therapeutics. Specific polymorphisms
(SNPs) in ESR1 may directly or indirectly lead to varia-
tions in its activity, and may have an effect on breast can-
cer risk. Although a number of studies have examined
SNPs located in estrogen related genes and possible asso-
ciations with mammographic density [25–36], few have
focused on premenopausal women [25, 27, 28, 33, 36],
and only a handful have considered SNPs in the ESR1
(rs2234693 and rs9340799) [25, 26, 29–31]. Further, none
have chacterized participants by menstrual cycle hormo-
nal milieu.
Previously, in the Norwegian Energy Balance and Breast
Cancer Aspects (EBBA)-I study, we observed a positive as-
sociation between daily circulating ovarian sex hormones
and both absolute and percent mammographic density
[15, 37]. In addition, daily 17β-estradiol profiles were posi-
tively associated with traditional breast cancer risk factors,
such as early age at menarche [38], short time since last
birth [39], and unfavourable metabolic profile [38, 40, 41].
We also observed associations between two SNPs in the es-
trogen pathway (rs7172156 and rs749292 in CYP19A1),
daily cycling 17β-estradiol, and absolute and percent mam-
mographic density [17] as well as between CYP17
(rs2486758) and metabolic risk factors [42] These associa-
tions also point to the need for further studies of estrogen,
mammographic density phenotypes and susceptibility genes
in combination. Here, we expand upon those results to
consider the ESR1 region, examining whether SNPs are
associated with daily cycling estradiol and premeno-
pausal mammographic density phenotypes.
Methods
Participants and study design
The Norwegian Energy Balance and Breast cancer Aspects I
study (EBBA-I) included a total of 204 healthy premeno-
pausal women, aged 25–35, recruited from the general
population by announcements in local newspapers, and
public meeting places. The study was conducted at the De-
partment of Clinical Research at the University Hospital of
Northern Norway (UNN), Tromsø, between 2000 and 2002
and has been described in detail elsewhere [14, 17, 38], we
briefly summarize the methods. The participating women
had to meet the following eligibility criteria: self-reported
regular menstruation (cycle length: 22–38 days within the
previous 3 months), no use of steroid contraceptives, preg-
nancy or lactation in the previous 6 months, no infertility,
no history of gynecological disorders, and no chronic disor-
ders (e.g. diabetes, hypo-/hyperthyroidism). At recruitment,
subjects completed questionnaires and were interviewed by
a trained nurse. Recall and memory-probing aids, including
a lifetime calendar, were used to date specific life events [14,
17, 38]. These interviews including items on demographics,
reproductive history, and lifestyle factors including: age at
menarche, marital status, education, ethnicity, parity, phys-
ical activity, previous use of hormonal contraceptives, family
history of cancer, smoking, and alcohol use [17, 38]. Birth
weight obtained from the questionnaire and interview was
also obtained by a linkage to the national Birth Registry.
Two women were excluded from the current analyses due
to missing mammographic data, resulting in 202 partici-
pants [38].
Clinical parameters
All participants underwent clinical examinations within
three specified intervals during a single menstrual cycle:
(1) between days 1–5 after onset of bleeding; (2) days
7–12; and (3) days 21–25. Height was measured to the
nearest 0.5 cm and weight to the nearest 0.1 kg on a
regularly calibrated electronic scale. Body mass index
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(BMI) for our analysis was calculated as weight in kilo-
grams per height in square meter (kg/m2) [38] using
data from the first visit. Waist circumference (WC) was
measured to the nearest 0.5 cm, 2.5 cm above the um-
bilicus. During the second visit a whole body scan was
obtained for the estimation of the total percentage of fat
tissue, using dual-energy X-ray absorptiometry (DEXA;
DPLX-L 2288, Lunar Radiation Corporation, Madison,
WI, USA). The percentage of fat tissue was estimated
using Lunar software [14, 17, 37].
Assessment of 17β-estradiol in serum and in saliva
At all three scheduled visits overnight fasting serum concen-
trations of 17β-estradiol were measured in fresh sera using a
direct immunometric assay (Immuno-1; Bayer Diagnostics,
Norway) at the Department of Clinical Chemistry, UNN
[38]. The sensitivity for estradiol was 0.01 nmol/L, and the
coefficient of variation (CV) was 3.9 %.
The participants self-collected daily morning saliva sam-
ples during the course of a whole menstrual cycle in order to
assess the daily bioavailable fraction of 17β-estradiol.
Sampling started on the first morning of menstrual bleeding
and was conducted according to previously established and
validated collection protocols [38, 43]. Samples were sent to
the Reproductive Ecology Laboratory at Harvard University
where they were stored at −70 °C until analysis. 17β-estradiol
concentrations were measured in each saliva sample using
125I- labeled RIA kits (#39100, Diagnostic Systems Labora-
tories, Webster, TX, USA). All samples were run in duplicate,
and samples from a single participant were run within the
same assay batch. CVs were calculated based on the high
and low value pools included in each assay [14, 17, 37].
Following estradiol assay, all cycles were aligned based on
the identification of the mid-cycle drop in salivary 17 β-
estradiol concentration (hereafter designated cycle day 0),
which provides a reasonable estimate of the day of ovulation
[17, 43, 44]. Two measures of 17β-estradiol were calculated
for all participants: mean cycle-long concentration and
mean mid-cycle (day −7 to +6) concentrations, as well as
using daily levels of salivary 17β-estradiol. The mid-cycle
17β-estradiol drop could not be identified for 14 women,
hence their cycles could not be aligned and they were omit-
ted from the statistical analysis [17].
Single-nucleotide polymorphism selection and genotyping
We analysed genetic polymorphisms in ESR1, 6q25, that
encodes the estrogen receptor α. DNA was extracted from
frozen whole blood using a MagAttract DNA Blood Mini
M48 kit (QIAGEN, Valencia, CA, USA) by the Department
of Medical Genetics, UNN. DNA was genotyped on the
Golden Gate Platform (Illumina, San Diego, CA, USA) at
the Fred Hutchinson Cancer Research Centre (Makar
Lab), using the manufacturer’s protocol [17]. These
methods have previously been described in detail [17]. In
brief, 250 ng of genomic DNA was divided into aliquots in
96-well plates, processed accordingly and scanned on the
Illumina iScan reader using BeadStudio software [17, 42].
We conducted a series of quality control procedures [45].
SNP call rates exceeded 99 % for this study, with 100 %
concordance of blinded duplicates. The linkage disequilibrium
select algorithm was employed to choose the tag SNPs via the
Genome Variation Server [46, 47]. The SNPs were selected
using an r2 threshold of 0.8 and a minor allele frequency
>5 %, representing variability in the white European popula-
tion. Tag SNP coverage extended 2 kilobases (kb) upstream
and 1 kb downstream of the gene, and 76 SNPs were covered.
We further reduced the number of SNPs using power calcu-
lations and ended up with a final selection of 34 common
SNPs with minor allele frequency >0.2. (Additional file 1:
Table S1) None of the selected SNPs were monomorphic or
significantly out of Hardy–Weinberg equilibrium [17].
Mammograms and mammographic density
We obtained bilateral two-view mammograms from our
subjects during the second scheduled visit (between cycle
days 7 and 12) at the Centre for Breast Imaging, UNN, using
a standard protocol [17, 38, 48]. The left craniocaudal mam-
mograms were digitised and imported into a computerised
mammographic density assessment programme (Madena)
developed at the University of Southern California School of
Medicine (Los Angeles, CA, USA) [38, 49, 50]. A single
trained reader (G. Ursin) conducted all density measure-
ments as follows: A region of interest (ROI) that included
the entire breast was identified, (excluding the pectoralis
muscle, prominent veins and fibrous strands). A tinting tool
was used to highlight pixels representing dense areas of the
mammograms within the ROI. The size of these dense areas
(in square centimetres) was automatically calculated by the
Madena software, giving a measure of absolute mammo-
graphic breast density [15, 38]. We then calculated percent-
age mammographic density as the ratio of absolute
mammographic breast density to total breast area multiplied
by 100 [37]. The mammograms were read in four batches,
with an equal number of mammograms included in each
batch. A duplicate reading of 26 randomly selected mammo-
grams from two of the batches showed a Pearson’s correl-
ation coefficient of 0.97. The reader was blinded to any
characteristics of the study population [14, 17, 37, 38].
Statistical methods
Descriptive characteristics were calculated by means (stand-
ard deviation) for continuous variables and percent for
binary data. On the basis of the plausible biological mecha-
nisms related to the estrogen metabolic pathway, we selected
34 SNPs in the ESR1, 6q25 gene for further analysis. These
SNPs were coded as AA= 0 (major homozygous), Aa= 1
(heterozygous) and aa= 2 (minor homozygous) [17].
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Mammographic density (absolute and percent) was
considered continuously in our first set of models. We used
multivariable linear regression models to assess the associ-
ation between mammographic density phenotypes (absolute
and percent mammographic density) as dependent variables
and ESR1 SNPs as ordinal independent variables.
Percent mammographic density and absolute mammo-
graphic density were used as both continuous and dichoto-
mized variables, representing lower and higher density, using
median values as cut-off points; Percent mammographic
density (28.5 %), and absolute mammographic density
(32.4 cm2) [16]. Previous studies of pre- and postmenopausal
women have observed a 2–3 fold increase in breast cancer
risk in women with percent mammographic density > 25 %
[8, 51] and absolute mammographic density > 32 cm2. These
observations along with our own observations related to
estradiol levels [15, 37] support the comparison of women
with above versus below median percent and absolute
mammographic density [16]. Thus, mammographic density
outcome variables were also used as dichotomized variables
in logistic regression models where indicator variables of
each SNP was included using aa as the reference level.
We considered several potential confounding factors
known to be associated with mammographic density pheno-
types, estrogen concentrations, and/or ESR1 variant. These
included age (continuous), BMI (continuous), birth weight
(continuous), age at menarche (continuous), parity (categor-
ical), previous oral contraceptive use (categorical) and current
smoking habits (categorical) [3]. Age, BMI, parity, current
smoking habits, and previous oral contraceptive use were in-
cluded as covariates in the final models. Salivary 17β-estradiol
(continuous) and birth weight [13, 40], did not influence
our estimates, and these were left out of our final model.
Based on plausible biological mechanisms and results from
the first set of models, we selected eight SNPs (rs3020364,
rs2474148, rs12154178, rs2347867, rs6927072, rs2982712,
rs3020407, rs9322335) for further analyses in which we
stratified the subjects based on median BMI (23.6 kg/m2).
We again fitted multivariable linear regression models using
the same set of covariates as previously specified, with the
exception of BMI, to show how the relationship between per-
cent mammographic density and the SNP genotypes might
vary among different strata of women. More detailed stratifi-
cation (i.e. to tertiles of body mass index) gave no additional
information. Thus, BMI was used both as a continuous vari-
able as well as a dichotomized one when we performed
stratified analysis (comparing low BMI vs high BMI).
We used linear mixed models for repeated measures to
study variations of daily salivary 17β-estradiol across the
menstrual cycle, for subgroups of women with either major,
minor homozygous or heterozygous genotypes for all eight
SNPs, and adjusted for current smoking habits (yes/no),
previous use of oral contraceptives (yes/no) as well as the
same confounders as in the initial linear regression models,
and stratified our data by median percent mammographic
density (28.5 %). This revealed a suggested pattern for
three of our eight SNPs (rs3020364, rs2474148, rs2982712).
All P-values were two-tailed and considered significant
when the value was <0.05. The analyses were conducted
with SPSS version 22.0 software (IBM, Armonk, NY, USA).
Results
Table 1 provides selected general characteristics of the
study participants. The participating women were on
average 30.7 years old and had a mean BMI of 24.4 kg/m2.
We found a mean salivary 17β-estradiol concentration
of 17.9 pmol/l, mean percent mammographic density
of 29.8 % (median 28.5 %), and mean absolute mam-
mographic density of 34.7 cm2 (median 32.4 cm2).
Common risk factors such as age, parity and body
composition (BMI, WC, and total tissue fat) were in-
versely associated with mammographic density pheno-
types. (Results not shown).
In our multiple linear regression models we found that
having the minor homozygous allele was associated with
decreased percent mammographic density for eight of our
34 SNPs: rs3020364 (p-value 0.01), rs2474148 (p-value
0.023), rs12154178 (p-value 0.026), rs2347867 (p-value
0.002), rs6927072 (p-value 0.007), rs2982712 p-value
0.006), rs3020407 (p-value 0.020), rs9322335 (p-value
0.024) (Table 2). For all but two (rs2347867, rs9322335)
of these eight SNPs this association was seen in lean,
but not in heavier women when we dichotomized our data
by median split of BMI (Lean: ≤23.6, Heavy > 23.6). With
the exception of rs9322335 (p-value 0.031), we did not ob-
serve similar associations in relation to absolute mammo-
graphic density (Additional file 2: Table S2).
The frequencies of genotypes of our selected SNPs in
the study population were similar to those recorded in
HapMap (Table 3). For seven out of eight SNPs, the
odds of above-median percent mammographic density
(>28.5 %) were 3–6 times higher among women with major
homozygous genotypes compared to women with minor
homozygous genotypes: rs3020364: OR 6.46 (p-value
0.009), rs2474148: OR 4.23 (p-value 0.028), rs12154178: OR
5.44 (p-value 0.014), rs2347867: OR 3.38 (p-value 0.030),
rs6927072: OR 3.44 (p-value 0.028), rs2982712: OR
3.97 (p-value 0.013), rs3020407: OR 3.97 (p-value 0.024).
When comparing the minor homozygous genotypes to the
heterozygous, the odds of above median mammographic
were higher for the heterozygous, but only significant for
rs2982712 (OR: 3.48, p-value 0.014) (Table 3).
When examining the 17β-estradiol concentrations
throughout the menstrual cycle for women with high and
low percent mammographic density separately (median
split of percent mammographic density) using linear mixed
models we found a striking, albeit only borderline sig-
nificant pattern for 3 of our 8 SNPs; the level of 17β-
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estradiol for women with the minor aa genotype for
rs3020364, rs24744148 and rs2982712 were lower
throughout the cycle for women with low (<28.5 %)
percent mammographic density and higher throughout
the cycle for women with high (>28.5 %) percent mammo-
graphic density, when compared to women with the major
AA genotype (Fig. 1) We observed a 24.3 % lower level of
mean 17β- estradiol throughout a menstrual cycle in
women with low mammographic density (<28.5 %) with
minor genotype aa of rs3020364 compared to those with
major genotype AA (Fig. 1a, p-value 0.076) and in women
with high mammographic density and minor genotype aa
of the same SNP we observed a 58 % higher level of mean
17β-estradiol throughout the cycle compared with women
with major genotype AA. (Fig. 1b: p-value 0.079). Fig. 1c-f
show a similar pattern for rs2474148 and rs2982714,
results in Fig. 1f are significant (p-value 0.025).
Table 2 The linear association between the selected SNPs in
the ESR1 region and percent mammographic density
SNPs BMI variable β-value 95 % CIa P-value
rs3020364 Ungroupedb −3.86 (−6.78, −0.95) 0.010
BMI median splitc
Low −6.17 (−11.1, −1.29) 0.014
High −3.61 (−7.40, 0.18) 0.062
rs2474148 Ungroupedb −3.37 (−6.26, −0.48) 0.023
BMI median splitc
Low −4.10 (−9.04, 0.85) 0.103
High −4.60 (−8.32, −0.89) 0.016
rs12154178 Ungroupedb −3.27 (−6.15, −0.39) 0.026
BMI median splitc
Low −5.93 (−19.6, −1.29) 0.013
High −3.29 (−7.02, 0.45) 0.084
rs2347867 Ungroupedb −4.24 (−6.97, −1.52) 0.002
BMI median splitc
Low −5.94 (−10.2, −1.71) 0.006
High −4.34 (−8.09, −0.60) 0.024
rs6927072 Ungroupedb −3.77 (−6.48, −1.06) 0.007
BMI median splitc
Low −5.57 (−9.87, −1.24) 0.012
High −4.30 (−7.95, −0.65) 0.022
rs2982712 Ungroupedb −3.89 (−6.67, −1.11) 0.006
BMI median splitc
Low −6.18 (−10.7, −1.62) 0.008
High −3.02 (−6.69, 0.64) 0.104
rs3020407 Ungroupedb −3.25 (−5.98, −0.51) 0.020
BMI median splitc
Low −5.23 (−9.55, −0.91) 0.180
High −3.27 (−6.91, 0.37) 0.078
rs9322335 Ungroupedb −3.46 (−6.46, −0.46) 0.24
BMI median splitc
Low −5.61 (−10.5, −0.73) 0.025
High −2.71 (−6.70, 1.29) 0.182
aConfidence Interval
bMultivariable linear regression, adjusted by age, BMI, age at menarche
and parity
cMultivariable linear regression, adjusted by age, age at menarche and parity.
BMI median split at 23.64 kg/m2
cOnly Single Nucleotide Polymorphisms (SNPs) with one or more two-tailed
p-values < 0.05 represented (8/34 selected SNPs with Minor allele
frequency (MAF) > 0.2)
Table 1 Selected characteristics of the study population: The
Norwegian EBBA-I study (n = 202)a
Characteristics Total study populationb
Age, years 30.7 (3.07)
Education, total years 16.1 (3.02)
Body compositionc
BMI, kg/m2 24.4 (3.77)
Waist, cm 79.5 (9.80)
Tissue fat, %e 34.2 (7.62)
Birth weight, g 3389 (561)
Reproductive factors
Parity, No children 0.91 (1.13)
Time since last birth among parous, years 4.72 (3.07)
Age at menarche, years 13.1 (1.36)
Cycle length, days 28.2 (3.17)
Follicular phase length, days 14.9 (1.73)
Luteal phase length, days 13.45 (1.73)
Salivary hormonesd
Overall average 17β-estradiol, pmol/l 17.9 (8.79)
Overall average progesterone, pmol/l 130.2 (68.3)
Serum hormonese
Estradiol, pmol/l 146.7 (61.6)
Progesterone, nmol/l 4.83 (6.29)
Lifestyle factors
Previous use of oral contraceptives, % 82.7
Leisure time, MET h/week 57.6 (88.6)
Alcohol intake, units per week 2.89 (3.38)
Current smokers, % 22.1
Mammogramsf
Percent mammographic density, % 29.8 (19.0)
Absolute mammographic density, cm2 34.7 (23.4)
Abbreviations; BMI body mass index, EBBA-1 The Norwegian Energy Balance
and Breast cancer Aspects Study 1
aNumbers may vary due to missing information
bValues are mean (SD) or percent
cMeasurements at day 1–5 after onset of menstrual cycle
dDaily saliva samples throughout an entire menstrual cycle
eSerum samples at day 7–12 (mid-cycle phase)
fMammograms and total tissue fat (DEXA) were taken at day 7–12 (mid-cycle
phase) after onset of the menstrual cycle
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Discussion
We have assessed the association between 34 polymor-
phisms in the ESR1 gene with mammographic density
phenotypes and daily cycling estradiol in healthy,
premenopausal, Norwegian women. Our results sup-
port an association between 8 (rs3020364, rs2474148,
rs12154178, rs2347867, rs6927072, rs2982712, rs3020407,
rs9322335) studied SNPs and percent mammographic
density, and one SNP (rs9322335) also associated with
absolute mammographic density. For all but two of these
SNPs (rs2347867, rs9322335) this inverse linear associ-
ation was maintained in lean (BMI ≤23.6 kg/m2), but not
in heavier women (BMI >23.6 kg/m2). We also suggest,
based on results of borderline significance that the level of
17β-estradiol for women with the minor aa genotype
for rs3020364, rs24744148 and rs2982712 were lower
Table 3 Selected SNP characteristics; Location, minor allele frequencies and adjusted Odds Ratio (OR) of above-median percent
mammographic density (>28.5 %) by genotypes
SNPa Location Alleles MAFb Genotype OR 95 % CIc P-value
EBBA-1 (HapMap)
rs302064 Intron A > G 0.368 (0.39)
aa 1.0 Ref Ref
Aa 3.74 0.95,14.6 0.059
AA 6.46 1.61, 25.9 0.009
rs2474148 Intron G > T 0.352 (0.35)
aa 1.0 Ref Ref
Aa 2.01 0.55, 7.39 0.29
AA 4.23 1.17, 15.6 0.028
rs12154178 Intron C < A 0.312 (0.26)
aa 1.0 Ref Ref
Aa 3.92 0.98, 7.39 0.054
AA 5.44 1.42, 20.9 0.014
rs2347867 Intron G > A 0.365 (0.30)
aa 1.0 Ref Ref
Aa 1.09 0.36, 3.29 0.879
AA 3.38 1.23, 10.1 0.030
rs6927072 Intron T > G 0.359 (0.28)
aa 1.0 Ref Ref
Aa 1.80 0.58, 5.56 0.309
AA 3.44 1.15, 10.3 0.028
rs2982712 Intron C < T 0.297 (−)
aa 1.0 Ref Ref
Aa 3.48 1.29, 9.36 0.014
AA 3.97 1.34, 11.7 0.013
rs3020407 Intron T < C 0.455 (0.47)
aa 1.0 Ref Ref
Aa 1.74 0.57, 10.3 0.331
AA 3.47 1.17, 10.3 0.024
rs9322335 Intron G > A 0.327 (0.27)
aa 1.0 Ref Ref
Aa 1.03 0.27, 3.88 0.969
AA 1.77 0.49, 6.40 0.388
Odds ratio from logistic regression model adjusted for age, age at menarche, BMI and parity
aSNP Single Nucleotide Polymorphisms
bMAF Minor allele frequency
cCI Confidence Interval
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Fig. 1 Salivary 17 β -estradiol levels across menstrual cycles for rs3020364, rs2474148, rs2982712. All analyses have used linear mixed models for
repeated measures adjusted for age, age at menarche, parity, body mass index, current smoking and previous oral contraceptives. 95 % confidence
intervals were removed for clarity. aa =minor homozygous genotype, Aa = heterozygous genotype, AA = major homozygous genotype. Mean
17β-estradiol levels by genotypes: a rs3020364 and low percent mammographic density (<28.5 %): aa (n = 23);14.0 pmol/L, Aa(n = 44); 19.2
pmol/L, AA(n = 28); 18.5. b rs3020364 and high percent mammographic density (≥28.5 %): aa (n = 21);29.0 pmol/L, Aa(n = 41); 18.7 pmol/L,
AA(n = 45); 18.3. c rs2474148 and low percent mammographic density (<28.5 %): aa (n = 21);14.0 pmol/L, Aa(n = 44); 19.1 pmol/L, AA(n = 30);
18.4. d rs2474148 and high percent mammographic density (≥28.5 %): aa (n = 5);28.4 pmol/L, Aa(n = 35); 18.2 pmol/L, AA(n = 51); 18.5. e rs2982712 and
low percent mammographic density (<28.5 %): aa (n = 31);15.1 pmol/L, Aa(n = 42); 19.4pmol/L, AA(n = 22); 18.4. f rs2982712 and high percent
mammographic density (≥28.5 %): aa (n = 10);25.9 pmol/L, Aa(n = 50); 17.4 pmol/L, AA(n = 31); 19.2
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throughout the cycle for women with low (<28.5 %)
percent mammographic density and higher throughout
the cycle for women with high (>28.5 %) percent mam-
mographic density, when compared to women with the
major AA genotype.
All 8 SNPs associated with mammographic density in
the present study are intronic. It is not yet clear why and
how noncoding SNPs influence the gene activity [17],
but one suggested mechanism is that intronic SNPs may
regulate gene expression through endogenous transact-
ing factors, epigenetics and chromosome conformation
[52]. Previous GWAS studies have shown intronic SNPs
to be important breast cancer risk loci [53]. This does
not imply causality, but may aid in the identification of
novel susceptibility loci [17]. The ERα-receptor mediates
estrogen action by regulating gene transcription, trigger-
ing the mRNA-synthesis and consequently the produc-
tion of proteins that produce the physiological hormone
effects [54]. The expression of ERα seems to be linked to
breast cell proliferation as well as to be increased during
tumorigenesis [55].
Since one of the mechanisms by which estrogen
promotes the proliferation of both normal and neo-
plastic breast epithelial cells is through its binding to
ERα, and that the content of ERα in breast tissue is
associated with increased breast cell proliferation [56,
57], a modification of the expression of this gene
could influence mammographic density or breast can-
cer risk. Indeed, a study among postmenopausal women
found a statistically significant increased protein expres-
sion of ERα in normal epithelium of women with high
mammographic density compared to those with low
density [58]. To our knowledge, there are no studies
related to ESR1 SNPs, daily levels of estrogens throughout
an entire menstrual cycle and mammographic density
phenotypes in premenopausal women, and published
results on the specific SNPs analysed in our current
study do not exist.
The possible associations between SNPs in the ER
genes and mammographic density are still under debate
[25, 26, 29–31]. Some in vitro studies have shown that
the expression of ERα in breast cancer cells may be
down regulated by estradiol [59]. Recently published
results from a study of 3,872 common genetic variants
across three ESR1 loci with subjects from three inter-
national consortia found evidence for at least five inde-
pendent causal variants associated with phenotype sets,
mammographic density being one. We found no evi-
dence of correspondence between our SNPs and the
causal variants identified, but this may be explained
by the fact that due to our small sample size we
identified 34 SNPs with a sufficient MAF >0.2, while
the newly published article could include the geno-
types of MAF > 0.02 [60].
Thus far, research has mostly focused on SNPs
rs2234693 (PvuII) or rs9340799 (XbaI). The impact of
PvuII and XbaI variant alleles on ESR1 transcription is
not well established. A recent meta-analysis including 11
studies identified reduced breast cancer risk for those
carrying homozygous the minor allele of SNP rs2234693,
while no association was observed for SNP rs9340799
[61]. Others have suggested that these variants are asso-
ciated with reduced breast cancer risk among women
with lower levels of estrogen [62, 63], and these findings
complement those emerging from some of the studies
on mammographic density: Among a population of
pre- and postmenopausal women, the minor allele of the
rs9340799 SNP was associated with decreased mammo-
graphic density, while no association was found for ERα
rs2234693 [29]. By contrast, others have found that pre-
menopausal women with the homozygous minor allele
of SNP rs2234693 (ERα) have higher mammographic
density. Similar associations have been suggested for
rs9340799 [25]. It is, therefore, plausible that estrogen
concentrations may influence the relationship between
susceptibility genes and mammographic density. This sug-
gests a biological rationale for our findings of different es-
trogen levels throughout the menstrual cycle of genotype
aa compared to AA when our population was split by per-
cent mammographic density (Fig. 1). Our results sug-
gest that having the minor homozygous allele is
associated with decreased percent mammographic dens-
ity, and the associations are stronger in lean women. How-
ever, no association has been observed within strata of
estrogen-related factors (parity, hormonal derivatives used,
age at menarche, BMI) among premenopausal women
[26], nor in populations of premenopausal and post-
menopausal women ([26, 30, 31]. Other investigated SNPs
(rs2228480, rs728524, rs3798577 and rs2077647) have
shown no association with mammographic density in pre-
menopausal and/or postmenopausal populations [25, 26].
Several of our findings are novel. To our knowledge,
no other studies have focused on the associations be-
tween mammographic density phenotypes and these 8
SNPs in the ESR1 gene. In a large case–control study, 41
independent breast cancer susceptibility variants were
discovered using a custom genotyping array designed, in
part, by the Breast Cancer Association Consortium [64].
Of these variants, a recent report found novel associa-
tions between breast cancer SNPs in 6q25 including
rs9383938 in the ESR1 region with a volumetric measure
of mammographic density in 5000 Swedish women [65].
The marker of density consortium (MODE) recently
identified nine loci associated with an area-based mam-
mographic density one of which is ESR1 [66, 67].
Specific SNPs located in genes of this pathway could
directly or indirectly lead to variations that may have
effects on breast cancer risk. Also, estrogens are known
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to regulate the activity of several enzymes and receptors
in the estrogen pathway [59, 68–70] Therefore, the
relation between SNPs of such genes and breast cancer
risk could vary among strata of women based on their
estradiol levels [71]. However, no overall linear associ-
ation was found between our SNPs and estradiol.
The strengths of our study include daily measurements
of salivary concentrations of unbound, bioactive 17β-
estradiol collected across an entire menstrual cycle [72], as
well as following strict procedures [38], and validated
methods [44]. Among ovulating premenopausal women,
the estrogen levels vary considerably throughout the men-
strual cycle [14]. Using daily salivary samples, we were able
to measure the free biologically active form of estrogen,
which is considered to be the ideal among ovulating
premenopausal women [14, 44, 73]. Previous research has
indicated that multiple measurements of unbound bio-
available levels probably give us a picture of the real and
cumulative estrogen exposure over time [7, 74]. Thus, we
were able to capture the continuous estrogen exposure of
the included women. We also included standardized re-
peated serum hormone levels. We have previously observed,
based on the same study population, that daily levels of saliv-
ary estradiol may be associated with known breast cancer
risk factors including mammographic density phenotypes
[15, 37]. Moreover, mammographic density measures were
obtained within a narrow time frame during the late follicu-
lar phase (days 7–12), thereby avoiding the bias of variation
in mammographic density throughout the menstrual cycle
[75]. The validated computer-assisted method used to quan-
tify mammographic density has been shown to give a super-
ior prediction of breast cancer risk compared to qualitative
methods [49]. A single experienced blinded reader read all
mammograms, and the assessed mammographic density
was negatively associated with age, BMI, and parity [76].
The relatively small sample size of the current study
must be considered as one of the limitations warranting
attention, and underlines the need for further and larger
studies. The study design was cross-sectional, and
population stratification can be of concern in this type
of study [77], but our study population consisted of
Norwegian/Caucasian women with only a ten-year age span.
Based on the biological hypothesis that polymorphisms in
the ESR1 gene may influence 17β-estradiol levels and
mammographic phenotypes, we examined a limited
number of SNPs [17]. Even though there is a risk of
false-positive results/type I errors in multiple testing,
our analysis are based on carefully considered plaus-
ible biological mechanisms, and an a priori hypothesis
of difference rather than a universal null-hypothesis.
Hence, we considered the increased likelihood of type
II errors and the risk of deeming truly interesting
difference non-significant when introducing Bonferroni-
adjustments just as important.
In recent studies, the immunoassay methods used in
the present study is most often replaced by Liquid
Chromatography (LC) - Mass Spectrometry (MS/MS),
which is considered a more efficient method of analysing
salivary hormones with higher specificity and sensitivity.
However, studies on estradiol measurements have demon-
strated a high correlation between LC/MS-MS and immu-
noassays of 0.969 [15, 17, 78].
Conclusions
The 6q25 region is important in the etiology of breast
cancer among women with dense breasts [79], but its
putative functions are still undefined. Identifying genetic
variants that are associated with both breast cancer risk
and mammographic density measures that predict breast
cancer has the potential to reveal underlying biological
pathways that explain the associations between those
mammographic measures and cancer. Our data provide
additional evidence for the relationship between genetic
variants, mammographic density phenotypes and estra-
diol. We hypothesize that ESR1 may play a role in the
relationship between dense breast tissue and estradiol
levels, and therefore, the risk of breast cancer.
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